Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
TLDR
In this article , the authors conducted two matched retrospective cohort studies to assess the effectiveness of booster vaccination, as compared with that of a two-dose primary series alone, against symptomatic SARS-CoV-2 infection and Covid-19-related hospitalization and death during a large wave of omicron infections from December 19, 2021, through January 26, 2022.Abstract:
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited efforts to scale up booster vaccination. Protection conferred by booster doses of the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines in Qatar, as compared with protection conferred by the two-dose primary series, is unclear.We conducted two matched retrospective cohort studies to assess the effectiveness of booster vaccination, as compared with that of a two-dose primary series alone, against symptomatic SARS-CoV-2 infection and Covid-19-related hospitalization and death during a large wave of omicron infections from December 19, 2021, through January 26, 2022. The association of booster status with infection was estimated with the use of Cox proportional-hazards regression models.In a population of 2,239,193 persons who had received at least two doses of BNT162b2 or mRNA-1273 vaccine, those who had also received a booster were matched with persons who had not received a booster. Among the BNT162b2-vaccinated persons, the cumulative incidence of symptomatic omicron infection was 2.4% (95% confidence interval [CI], 2.3 to 2.5) in the booster cohort and 4.5% (95% CI, 4.3 to 4.6) in the nonbooster cohort after 35 days of follow-up. Booster effectiveness against symptomatic omicron infection, as compared with that of the primary series, was 49.4% (95% CI, 47.1 to 51.6). Booster effectiveness against Covid-19-related hospitalization and death due to omicron infection, as compared with the primary series, was 76.5% (95% CI, 55.9 to 87.5). BNT162b2 booster effectiveness against symptomatic infection with the delta (or B.1.617.2) variant, as compared with the primary series, was 86.1% (95% CI, 67.3 to 94.1). Among the mRNA-1273-vaccinated persons, the cumulative incidence of symptomatic omicron infection was 1.0% (95% CI, 0.9 to 1.2) in the booster cohort and 1.9% (95% CI, 1.8 to 2.1) in the nonbooster cohort after 35 days; booster effectiveness against symptomatic omicron infection, as compared with the primary series, was 47.3% (95% CI, 40.7 to 53.3). Few severe Covid-19 cases were noted in the mRNA-1273-vaccinated cohorts.The messenger RNA (mRNA) boosters were highly effective against symptomatic delta infection, but they were less effective against symptomatic omicron infection. However, with both variants, mRNA boosters led to strong protection against Covid-19-related hospitalization and death. (Funded by Weill Cornell Medicine-Qatar and others.). read more
Citations
More filters
Journal ArticleDOI
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
TL;DR: In this paper , the authors evaluated the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), natural immunity due to previous infection with variants other than omicron, and hybrid immunity (previous infection and vaccination) against SARS-CoV-2.1 and BA.2.
Journal ArticleDOI
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Hiam Chemaitelly,Houssein H. Ayoub,Sawsan AlMukdad,Peter Coyle,Peipei Tang,Hadi M. Yassine,Hebah A. Al-Khatib,Maria K. Smatti,Maryatun Hasan,Zaina Al-Kanaani,Einas Alkuwari,Andrew Jeremijenko,Anvar Hassan Kaleeckal,Ali Nizar Latif,Riyazuddin Mohammad Shaik,Hanan F. Abdul-Rahim,Gheyath K. Nasrallah,Mohamed Ghaith Al-Kuwari,Adeel A. Butt,Hamad Al-Romaihi,Mohamed H. Al-Thani,Abdullatif Al-Khal,Roberto Bertollini,Lja Abu-Raddad +23 more
TL;DR: In this paper , the authors conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 vaccines against BA.1 and BA.2 infections in Qatar.
Journal ArticleDOI
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
Panke Qu,John P. Evans,Julia Faraone,Yibin Zheng,Claire Carlin,Mirela Anghelina,P K Stevens,Soledad Fernandez,Dan Jones,Gerard Lozanski,Ashish Panchal,Linda J. Saif,E. M. Oltz,Kai Xu,Richard J. Gumina,Shan Lu +15 more
TL;DR: In this article , the authors examined the neutralization resistance of SARS-CoV-2 Omicron subvariants against sera from 3-dose vaccinated healthcare workers, hospitalized BA.1.4/5-wave patients, and BA.2.2 subvariant driven largely by its F486S mutation.
Journal ArticleDOI
COVID-19 Disease Severity in Children Infected with the Omicron Variant
Adeel A. Butt,Soha R. Dargham,Srusvin Loka,Riyazuddin Mohammad Shaik,Hiam Chemaitelly,Patrick Tang,M. Z. Hasan,Peter V. Coyle,Hadi M. Yassine,Hebah A. Al-Khatib,Maria K. Smatti,Anvar Hassan Kaleeckal,Ali Nizar Latif,Ahmed Zaqout,Muna Almaslamani,Abdullatif Al Khal,Roberto Bertollini,Abdul B. Abou-Samra,Laith J. Abu-Raddad +18 more
TL;DR: Omicron variant infection in children/adolescents is associated with less severe disease than Delta variant infection as measured by hospitalization rates and need for ICU care or mechanical ventilation.
Journal ArticleDOI
Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study
TL;DR: A fourth dose of the BNT162b2 vaccine appears to have provided additional protection against both SARS-CoV-2 infection and severe covid-19 disease relative to three vaccine doses, however, relative effectiveness of the fourth dose against infection appears to wane sooner than that of the third dose.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research
TL;DR: The utility and interpretation of the standardized difference for comparing the prevalence of dichotomous variables between two groups is explored, and a standardized difference of 10% is equivalent to having a phi coefficient of 0.05 for the correlation between treatment group and the binary variable.
Journal ArticleDOI
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available
Miguel A. Hernán,James M. Robins +1 more
TL;DR: This work outlines a framework for comparative effectiveness research using big data that makes the target trial explicit and channels counterfactual theory for comparing the effects of sustained treatment strategies, organizes analytic approaches, provides a structured process for the criticism of observational studies, and helps avoid common methodologic pitfalls.
Journal ArticleDOI
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
TL;DR: Efficacy of the BNT162b2 mRNA Vaccine in Qatar As of March 31, 2021, more than 265,000 people in Qatar had received both doses of the vaccine as mentioned in this paper.
Journal ArticleDOI
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
TL;DR: In this article , the clinical severity of COVID-19 omicron variant using S gene target failure (SGTF) on the Thermo Fisher Scientific TaqPath COVID19 PCR test as a proxy was assessed using multivariable logistic regression models.
Related Papers (5)
Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT1262b2 and after booster vaccination with BNT1262b2 or mRNA-1273: a population-based cohort study (COVIDENCE UK)
Adrian R. Martineau,Adam Geczy +1 more